Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
OPERATING ACTIVITIES:
Consolidated net loss	$ (3,078,000)	$ 1,448,000
Adjustments to reconcile consolidated net (loss) income to net cash provided by (used in) operating activities:
Bad debt expense	102,000	15,000
Depreciation and amortization	2,433,000	1,690,000
Stock-based compensation expense	898,000	689,000
Amortization of debt issuance cost	9,000	6,000
Tax payments related to shares cancelled for vested restricted stock awards	(12,000)	(21,000)
Deferred income taxes	(677,000)	(1,427,000)
Changes in operating assets and liabilities:
Trade accounts receivable	4,433,000	1,496,000
Inventories	2,323,000	(6,150,000)
Other current assets	3,713,000	(2,894,000)
Right of use assets	1,477,000	3,378,000
Other long-term assets	(18,000)	225,000
Accounts payable	(2,451,000)	1,065,000
Accrued expenses	(4,244,000)	3,063,000
Income taxes payable	(759,000)	759,000
Net cash provided by operating activities	4,185,000	2,892,000
INVESTING ACTIVITIES:
Capital expenditures	(2,483,000)	(2,675,000)
Purchase of Microlab, net of cash acquired ($33)	0	(24,442,000)
Net cash used in investing activities	(2,483,000)	(27,117,000)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	87,000	150,000
Debt issuance cost	0	(32,000)
Line of credit payments	1,000,000	(0)
Revolving credit facility	2,000,000	(0)
Term Loan payments	(2,424,000)	(1,414,000)
Term Loan	0	17,000,000
Net cash (used in) provided by financing activities	(1,337,000)	15,704,000
Net decrease in cash and cash equivalents	365,000	(8,521,000)
Cash and cash equivalents, beginning of period	4,532,000	13,053,000
Cash and cash equivalents, end of period	4,897,000	4,532,000
Supplemental cash flow information – income taxes paid	$ 642,000	$ (314,000)